InspireMD Basic EPS 2013-2025 | NSPR
InspireMD basic eps from 2013 to 2025. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| InspireMD Annual Basic EPS | |
|---|---|
| 2024 | $-0.76 |
| 2023 | $-0.82 |
| 2022 | $-2.35 |
| 2021 | $-2.03 |
| 2020 | $-6.97 |
| 2019 | $-71.96 |
| 2018 | $-249.93 |
| 2017 | $-26,221.89 |
| 2016 | $-155,712.20 |
| 2015 | $-1,463,866.00 |
| 2014 | $-7.09 |
| 2013 | $0.00 |
| 2013 | $-1.39 |
| 2012 | $0.00 |
| 2012 | $-1.04 |
| 2011 | $0.00 |
| InspireMD Quarterly Basic EPS | |
|---|---|
| 2025-03-31 | $-0.22 |
| 2024-12-31 | $-0.17 |
| 2024-09-30 | $-0.16 |
| 2024-06-30 | $-0.22 |
| 2024-03-31 | $-0.21 |
| 2023-12-31 | $0.10 |
| 2023-09-30 | $-0.15 |
| 2023-06-30 | $-0.24 |
| 2023-03-31 | $-0.53 |
| 2022-12-31 | $-0.61 |
| 2022-09-30 | $-0.58 |
| 2022-06-30 | $-0.59 |
| 2022-03-31 | $-0.57 |
| 2021-12-31 | $-0.51 |
| 2021-09-30 | $-0.53 |
| 2021-06-30 | $-0.46 |
| 2021-03-31 | $-0.53 |
| 2020-12-31 | $3.34 |
| 2020-09-30 | $-0.96 |
| 2020-06-30 | $-2.93 |
| 2020-03-31 | $-6.42 |
| 2019-12-31 | $28.04 |
| 2019-09-30 | $-18.89 |
| 2019-06-30 | $-23.84 |
| 2019-03-31 | $-57.27 |
| 2018-12-31 | $711.54 |
| 2018-09-30 | $-37.03 |
| 2018-06-30 | $-114.84 |
| 2018-03-31 | $-809.60 |
| 2017-12-31 | $5,389.81 |
| 2017-09-30 | $-4,917.54 |
| 2017-06-30 | $-5,472.26 |
| 2017-03-31 | $-21,221.89 |
| 2016-12-31 | $169,562.30 |
| 2016-09-30 | $-22,279.07 |
| 2016-06-30 | $-119,520.70 |
| 2016-03-31 | $-183,474.70 |
| 2015-12-31 | $-1,151,171.00 |
| 2015-09-30 | $-312,693.30 |
| 2015-06-30 | $-0.51 |
| 2015-03-31 | $-1.04 |
| 2014-12-31 | $-4.73 |
| 2014-09-30 | $-1.96 |
| 2014-06-30 | $-0.22 |
| 2014-03-31 | $-0.18 |
| 2013-12-31 | |
| 2013-09-30 | $-0.12 |
| 2013-06-30 | $-0.48 |
| 2013-03-31 | $-0.27 |
| 2012-12-31 | |
| 2012-09-30 | $-0.44 |
| 2012-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.072B | $0.007B |
| InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel. | |||